1074 related articles for article (PubMed ID: 18729848)
1. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.
Elnachef N; Scheiman JM; Fendrick AM; Howden CW; Chey WD
Aliment Pharmacol Ther; 2008 Nov; 28(10):1249-58. PubMed ID: 18729848
[TBL] [Abstract][Full Text] [Related]
2. Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey.
Chey WD; Eswaren S; Howden CW; Inadomi JM; Fendrick AM; Scheiman JM
Aliment Pharmacol Ther; 2006 Mar; 23(5):655-68. PubMed ID: 16480405
[TBL] [Abstract][Full Text] [Related]
3. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
4. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
Joshua FF; Oakley SP; Major GA
Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
[TBL] [Abstract][Full Text] [Related]
5. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
6. Long-term NSAID use in primary care: changes over a decade and NICE risk factors for gastrointestinal adverse events.
Thompson PW; Tee L; McBride J; Quincey D; Strat Liddiard G
Rheumatology (Oxford); 2005 Oct; 44(10):1308-10. PubMed ID: 15972345
[TBL] [Abstract][Full Text] [Related]
7. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
[TBL] [Abstract][Full Text] [Related]
8. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Rostom A; Moayyedi P; Hunt R;
Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
[TBL] [Abstract][Full Text] [Related]
9. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
Moore RA; Derry S; Phillips CJ; McQuay HJ
BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
[TBL] [Abstract][Full Text] [Related]
10. Nonsteroidal anti-inflammatory drugs, aspirin, and gastrointestinal prophylaxis: an ounce of prevention.
Scheiman JM
Rev Gastroenterol Disord; 2005; 5 Suppl 2():39-49. PubMed ID: 16369226
[TBL] [Abstract][Full Text] [Related]
11. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
Moride Y; Ducruet T; Boivin JF; Lavoie F; Rochon S
Can J Clin Pharmacol; 2005; 12(2):e201-11. PubMed ID: 15998959
[TBL] [Abstract][Full Text] [Related]
12. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
Dai C; Stafford RS; Alexander GC
Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363
[TBL] [Abstract][Full Text] [Related]
13. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
van den Bemt BJ; Benraad HB; Rasker JJ
Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414
[TBL] [Abstract][Full Text] [Related]
15. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
16. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis.
Ofman JJ; Badamgarav E; Henning JM; Knight K; Laine L
Am J Med; 2004 Jun; 116(12):835-42. PubMed ID: 15178499
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
Wong M; Chowienczyk P; Kirkham B
Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
[TBL] [Abstract][Full Text] [Related]
18. A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs.
Nakashima S; Arai S; Mizuno Y; Yoshino K; Ando S; Nakamura Y; Sugawara K; Koike M; Saito E; Naito M; Nakao M; Ito H; Hamaoka K; Rai F; Asakura Y; Akamatu M; Fujimori K; Inao M; Imai Y; Ota S; Fujiwara K; Shiibashi M
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():60-6. PubMed ID: 15943849
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
Joshi GP; Gertler R; Fricker R
Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
Chen JT; Pucino F; Resman-Targoff BH
J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
